US Top Rating Updates on 12/19: TSLA, T, MRNA, XYL and More

Jefferies analyst Michael Yee upgraded $Moderna(MRNA.US)$ to Buy from Hold with a price target of $275, up from $170. The shares can rebound in 2023 given the company's pipeline opportunities, Yee tells investors in a research note. He believes Moderna is the "new shiny thing" in personalized cancer vaccine following the recent positive Phase 2 data.

Atlantic Equities analyst Hamilton Faber upgraded $Warner Music(WMG.US)$ to Overweight from Neutral with a price target of $41, up from $34. The analyst's research shows music streaming subscriptions growing at 10% annually over the next ten years. In addition, recent results show Warner Music can deliver solid growth in spite of a difficult economic backdrop, Faber tells investors in a research note.

Stifel analyst Nathan Jones upgraded $Pentair(PNR.US)$ to Buy from Hold with a price target of $57, up from $46. The analyst also added the shares to the "Stifel Select List." 2022 has been a difficult year for the shares as the overhang from potential demand pull forward during COVID and inventory destocking to come have weighed heavily on investor sentiment, Jones tells investors in a research note.